Core Insights - Pfizer is a leading American multinational pharmaceutical and biotechnology company, known for its rapid development of the Comirnaty Covid-19 vaccine and Paxlovid treatment, and is expanding its oncology portfolio and entering the obesity market with danuglipron [1] Financial Performance - For Q4 2025, Pfizer reported $17.6 billion in revenue, exceeding analyst estimates and reflecting a 9% operational growth when excluding Covid-19 products [6] - Adjusted diluted EPS for the quarter was $0.66, significantly higher than the forecasted $0.58 [6] - The company's core biopharma business remained strong, with recently launched and acquired products contributing $10.2 billion in full-year revenue [7] Market Position - Pfizer has a market capitalization of approximately $156 billion and offers a robust 6.91% dividend yield, making it attractive for income-oriented investors [3] - The company outperformed the S&P 500 Health Care Index, returning roughly 4.3% annually, while the index remained flat [4] - Pfizer is in a value-oriented "base-building" phase, focusing on consistent shareholder returns rather than aggressive capital appreciation as it integrates new acquisitions [4]